Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI

The microflora-sparing properties of fidaxomicin were examined during the conduct of a randomized clinical trial comparing vancomycin 125 mg 4 times per day versus fidaxomicin 200 mg twice per day for 10 days as treatment of Clostridium difficile infection (CDI). Fecal samples were obtained from 89...

Descripción completa

Detalles Bibliográficos
Autores principales: Louie, Thomas J., Cannon, Kris, Byrne, Brendan, Emery, Judy, Ward, Linda, Eyben, Melissa, Krulicki, Walter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2012
Materias:
Supplement Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388020/
https://www.ncbi.nlm.nih.gov/pubmed/22752862
http://dx.doi.org/10.1093/cid/cis338

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388020/
https://www.ncbi.nlm.nih.gov/pubmed/22752862
http://dx.doi.org/10.1093/cid/cis338

Ejemplares similares